GSK seeks FDA approval for asthma treatment
Research Triangle Park, N.C. —
The British company’s once-a-day inhaled corticosteroid treatment would be administered by the the Ellipta dry powder inhaler. GSK is seeking approval for fluticasone furoate monotherapy as a maintenance treatment of asthma in patients 12 years old and older.
GSK plans to file for approval of the treatment in other countries next year. GSK operates its U.S. headquarters in Research Triangle Park.
Please Log In to add a comment.
Best of TechWire Insider
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution
- Can Barley's bark win Super Bowl gold for Durham startup?
- Tech guru Mossberg changes gears, praises Republic Wireless
- Survey explodes myth of the poor VC-backed entrepreneur
- Analyze this: SAS steps up education commitment with Teradata deal
- Web Foundation report reflects concerns about US security state
- IBM bashes Bridgestone after tire giant sues for $600M